Ono Pharmaceutical Co., Ltd.
OPHLF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $876,096 | $127,536,000 | $112,309,000 | $134,223,000 |
| % Growth | -99.3% | 13.6% | -16.3% | – |
| Cost of Goods Sold | $236,350 | $37,013,000 | $45,237,000 | $45,836,000 |
| Gross Profit | $639,746 | $90,523,000 | $67,072,000 | $88,387,000 |
| % Margin | 73% | 71% | 59.7% | 65.9% |
| R&D Expenses | $235,038 | $36,252,000 | $42,794,000 | $38,269,000 |
| G&A Expenses | $0 | $0 | $1,211,000 | $0 |
| SG&A Expenses | $203,375 | $31,086,000 | $31,932,000 | $35,315,000 |
| Sales & Mktg Exp. | $0 | $0 | $30,651,000 | $0 |
| Other Operating Expenses | $0 | $1,190,000 | $3,353,000 | -$70,000 |
| Operating Expenses | $438,413 | $68,528,000 | $78,079,000 | $73,514,000 |
| Operating Income | $201,333 | $21,995,000 | -$11,007,000 | $14,873,000 |
| % Margin | 23% | 17.2% | -9.8% | 11.1% |
| Other Income/Exp. Net | -$1,744 | $655,000 | -$1,701,000 | $2,527,000 |
| Pre-Tax Income | $199,589 | $22,650,000 | -$12,708,000 | $17,400,000 |
| Tax Expense | $48,496 | $5,019,000 | -$6,341,000 | $2,514,000 |
| Net Income | $152,093 | $17,673,000 | -$6,545,000 | $14,951,000 |
| % Margin | 17.4% | 13.9% | -5.8% | 11.1% |
| EPS | 0.32 | 37.62 | -13.93 | 31.83 |
| % Growth | -99.1% | 370.1% | -143.8% | – |
| EPS Diluted | 0.32 | 37.58 | -13.97 | 31.81 |
| Weighted Avg Shares Out | 469,853 | 470,277 | 465,562 | 469,994 |
| Weighted Avg Shares Out Dil | 470,277 | 470,277 | 469,758 | 469,994 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,577 | $655,000 | $0 | $2,526,000 |
| Interest Expense | $8,288 | $0 | $1,824,000 | $0 |
| Depreciation & Amortization | $62,956 | $9,238,000 | $8,728,000 | $9,170,000 |
| EBITDA | $270,833 | $31,233,000 | -$5,788,000 | $24,045,000 |
| % Margin | 30.9% | 24.5% | -5.2% | 17.9% |